01
Market and channel design
Define the practice segments, account priorities, routes to market, partner roles, and commercial assumptions that should shape the launch.
Aesthetic medicine commercialization
Commercialize aesthetic products through the practices that adopt, recommend, and use them.
UEM supports smaller and growth-stage manufacturers bringing injectables, professional skincare, and other practice-dispensed aesthetic products into U.S. dermatology, plastic-surgery, medical-office, and med-spa channels.
Discuss an aesthetic launch
Practice adoption · Channel design · Commercial discipline
Dermatology practices
Plastic-surgery practices
Medical offices
Med-spa networks
Commercialization capabilities
A practice-based market needs more than consumer marketing.
Success depends on the product, the provider, the practice team, the channel, and the patient experience working as one commercial system. UEM helps leadership make those connections explicit and govern the decisions behind them.
02
Provider and practice adoption
Connect product positioning with provider education, practice economics, staff confidence, patient experience, and the realities of adoption inside a professional setting.
03
Commercial team and network design
Design the right field, inside, distributor, training, and account-support model for the product, channel, geography, and stage of growth.
04
Launch governance and measurement
Make claims, evidence, owners, dependencies, risks, milestones, and performance signals visible before commercial activity outruns the operating system.
The operating distinction
The discipline carries over. The market assumptions do not.
UEM brings the same evidence, readiness, organization, channel, and executive decision discipline used in regulated commercialization. Aesthetic medicine, however, has its own provider economics, purchase patterns, training needs, customer experience, and routes to adoption.
We do not copy a pharmaceutical launch template into an aesthetic business. The operating model is designed around the product category, the intended practice setting, the evidence available, and the capabilities the organization can support.
Named-brand affiliations, client outcomes, and clinical claims are never implied without authorization and evidence.
Connected work
ClearSpec Labs
UEM contributes commercialization and operating-model perspective to ClearSpec Labs, a separate Seven16 Group research-commerce initiative built around clearer product information and evidence governance.
ClearSpec Labs' current public catalog is for research use only. It is not a source of products for human or veterinary use.
Visit ClearSpec LabsSystem direction
RxLaunchOS for aesthetic medicine
This work is informing a future aesthetic-medicine configuration of UEM's commercialization operating system: separate sector methodology, shared decision discipline, and no reuse of pharmaceutical assumptions as aesthetic-market facts.
The sector configuration is exploratory and is not represented as a generally available, off-the-shelf product today.
Explore the RxLaunchOS modelStart with the market decision